These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25189926)

  • 1. Rebasing the Medicare payment for dialysis: rationale, challenges, and opportunities.
    Wish D; Johnson D; Wish J
    Clin J Am Soc Nephrol; 2014 Dec; 9(12):2195-202. PubMed ID: 25189926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bundled payment for ESRD--including ESAs in Medicare's dialysis package.
    Iglehart JK
    N Engl J Med; 2011 Feb; 364(7):593-5. PubMed ID: 21323538
    [No Abstract]   [Full Text] [Related]  

  • 3. Practice patterns, case mix, Medicare payment policy, and dialysis facility costs.
    Hirth RA; Held PJ; Orzol SM; Dor A
    Health Serv Res; 1999 Feb; 33(6):1567-92. PubMed ID: 10029498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare program; end-stage renal disease prospective payment system. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2010 Aug; 75(155):49029-214. PubMed ID: 20712086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
    Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
    BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
    Brunelli SM; Monda KL; Burkart JM; Gitlin M; Neumann PJ; Park GS; Symonian-Silver M; Yue S; Bradbury BD; Rubin RJ
    Am J Kidney Dis; 2013 Jun; 61(6):947-56. PubMed ID: 23332991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What can we learn from the U.S. expanded end-stage renal disease bundle?
    Chambers JD; Weiner DE; Bliss SK; Neumann PJ
    Health Policy; 2013 May; 110(2-3):164-71. PubMed ID: 23419419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization.
    Bhat P; Sokolowski W; Bhat JG
    Nephrol News Issues; 2009 Jun; 23(7):46, 48-52. PubMed ID: 19585810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
    Park H; Rascati KL; Keith MS
    J Manag Care Spec Pharm; 2015 Jun; 21(6):507-14. PubMed ID: 26011552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The initial impact of Medicare's new prospective payment system for kidney dialysis.
    Hirth RA; Turenne MN; Wheeler JR; Nahra TA; Sleeman KK; Zhang W; Messana JA
    Am J Kidney Dis; 2013 Oct; 62(4):662-9. PubMed ID: 23769138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
    Charytan C
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism.
    Gupta C; Chertow GM; Linthicum MT; Van Nuys K; Belozeroff V; Quarles D; Lakdawalla DN
    Health Serv Res; 2014 Dec; 49(6):1925-43. PubMed ID: 25040130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
    Liu FX; Walton SM; Leipold R; Isbell D; Golper TA
    Perit Dial Int; 2014; 34(7):749-57. PubMed ID: 25292402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs.
    Swaminathan S; Mor V; Mehrotra R; Trivedi A
    Health Aff (Millwood); 2012 Sep; 31(9):2051-8. PubMed ID: 22949455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents.
    Swaminathan S; Mor V; Mehrotra R; Trivedi AN
    Health Serv Res; 2015 Jun; 50(3):790-808. PubMed ID: 25355431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing mandated health care reforms: the Affordable Care Act, accountable care organizations, and the Medicare ESRD program.
    Watnick S; Weiner DE; Shaffer R; Inrig J; Moe S; Mehrotra R;
    Clin J Am Soc Nephrol; 2012 Sep; 7(9):1535-43. PubMed ID: 22626961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes and alternatives for dialysis facilities under the bundled payment plan.
    Solid CA; Collins AJ
    Nephrol News Issues; 2013 May; 27(6):30-2. PubMed ID: 23729081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Dialysis and its Financing.
    Borelli M; Paul DP; Skiba M
    Hosp Top; 2016; 94(2):33-8. PubMed ID: 27315562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
    Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
    BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.